This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pennington, J E Articles by Pier, G B Search for Related Content PubMed PubMed Citation Articles by Pennington, J E Articles by Pier, G B

Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

ABSTRACT

A human immunoglobulin G preparation, enriched in antibodies to lipopolysaccharide (LPS) Pseudomonas aeruginosa antigens (PA-IGIV) and murine monoclonal antibodies (MAb) to P. aeruginosa Fisher immunotype-1 (IT-1) LPS antigen and outer membrane protein F (porin), were evaluated for therapeutic efficacy in a guinea pig model of P. aeruginosa pneumonia. The concentration of antibodies to IT-1 LPS was 7.6 micrograms/ml in PA-IGIV and 478 micrograms/ml in the IT-1 MAb preparation. No antibody to IT-1 was detected in MAb to porin. For study, animals were infected by intratracheal instillation of IT-1 P. aeruginosa and then treated 2 h later with intravenous infusions of PA-IGIV, IT-1 MAb, or porin MAb. Control groups received intravenous albumin, and routinely died from pneumonia. Both PA-IGIV (500 mg/kg) and IT-1 MAb (greater than or equal to 2.5 mg/kg) treatment resulted in increased survival (P less than 0.01 to 0.001), and also improved intrapulmonary killing of bacteria. Porin MAb failed to protect from fatal pneumonia. IT-1 MAb treatment produced more survivals than did PA-IGIV treatment but only at dosages of MAb resulting in serum antibody concentrations greater than those achieved with PA-IGIV. PA-IGIV and IT-1 MAb demonstrated in vitro and in vivo (posttreatment guinea pig serum) opsonophagocytic activity for the IT-1 challenge strain. However, the polyclonal preparation required complement, whereas the MAb did not. We conclude that passive immunization with polyclonal hyperimmune P. aeruginosa globulin or with MAb to LPS antigens may be useful in the treatment of acute P. aeruginosa pneumonia. The relative efficacies of such preparations may be limited, however, by their type-specific LPS antibody concentrations.

This article has been cited by other articles:

• Wolfe, D. N., Goebel, E. M., Bjornstad, O. N., Restif, O., Harvill, E. T. (2007). The O Antigen Enables Bordetella parapertussis To Avoid Bordetella pertussis-Induced Immunity. Infect. Immun. 75: 4972-4979 [Abstract] [Full Text]  
• Wolfe, D. N., Kirimanjeswara, G. S., Goebel, E. M., Harvill, E. T. (2007). Comparative Role of Immunoglobulin A in Protective Immunity against the Bordetellae. Infect. Immun. 75: 4416-4422 [Abstract] [Full Text]  
• Zaidi, T. S., Priebe, G. P., Pier, G. B. (2006). A Live-Attenuated Pseudomonas aeruginosa Vaccine Elicits Outer Membrane Protein-Specific Active and Passive Protection against Corneal Infection. Infect. Immun. 74: 975-983 [Abstract] [Full Text]  
• Matsumoto, T., Tateda, K., Miyazaki, S., Furuya, N., Ohno, A., Ishii, Y., Hirakata, Y., Yamaguchi, K. (1999). Effect of Antiflagellar Human Monoclonal Antibody on Gut-Derived Pseudomonas aeruginosa Sepsis in Mice. CVI 6: 537-541 [Abstract] [Full Text]  
• Rawling, E. G., Brinkman, F. S. L., Hancock, R. E. W. (1998). Roles of the Carboxy-Terminal Half of Pseudomonas aeruginosa Major Outer Membrane Protein OprF in Cell Shape, Growth in Low-Osmolarity Medium, and Peptidoglycan Association. J. Bacteriol. 180: 3556-3562 [Abstract] [Full Text]